Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970348 | 0.85 | TLR8 (0.34) | TLR8TLR7 | |
| SCHEMBL16604738 | 0.83 | TLR8 (0.33) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL16604761 | 0.81 | — | — | |
| SCHEMBL16593550 | 0.74 | SELE (0.47) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL1193873 | 0.74 | ADORA3 (0.33) | NPC1RAB9A | |
| SCHEMBL16604788 | 0.73 | — | — | |
| SCHEMBL19327472 | 0.73 | ALDH1A1 (0.32) | — | |
| SCHEMBL17926550 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL16604771 | 0.69 | TLR8 (0.31) | TLR8TLR7 | |
| SCHEMBL16604785 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3049086-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
| WO-2015048281-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
| WO-2015048281-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | NPC1 2078/4885GAA 2264/4885MAPK1 1813/4885 |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 1962/4885GAA 2969/4885MAPK1 780/4885 |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 1962/4885GAA 2969/4885MAPK1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.